Pharmaceutical formulation firm Rubicon Analysis Ltd has filed draft papers with capital markets regulator Sebi to garner Rs 1,085 crore by way of an preliminary share sale.
The corporate’s Preliminary Public Providing (IPO) is a mixture of a contemporary situation of fairness shares value Rs 500 crore and an Provide For Sale (OFS) of shares valued at Rs 585 crore by promoter, Common Atlantic Singapore RR Pte Restricted, in line with the Draft Pink Herring Prospectus (DRHP) filed on Wednesday.
At current, Common Atlantic owns over 57 per cent stake in Rubicon Analysis.
The corporate proposes to utilise proceeds from the contemporary situation to the tune of Rs 310 crore for cost of debt. Additionally, funds shall be used for supporting inorganic progress by way of unidentified acquisitions in addition to different strategic initiatives and normal company functions.
Rubicon Analysis is a pharmaceutical formulations firm, pushed by innovation by way of targeted analysis and growth, with an rising portfolio of speciality merchandise and drug-device mixture merchandise focusing on regulated markets and particularly the USA.
The pharma agency has two USFDA-inspected analysis and growth (R&D) amenities –one every in India and Canada — and two manufacturing amenities in India with a number of accreditations from a number of regulatory companies reminiscent of USFDA, Meals and Medication Administration, Maharashtra (WHO-GMP accreditation) and Well being Canada.
As on March 31, 2024, Rubicon Analysis had a portfolio of 69 merchandise authorised by the USFDA, 19 new medicine awaiting USFDA’s nod and 46 merchandise in numerous levels of growth.
Axis Capital, IIFL Securities, and SBI Capital Markets are the ebook operating lead managers to the difficulty.
(Solely the headline and film of this report could have been reworked by the Enterprise Commonplace workers; the remainder of the content material is auto-generated from a syndicated feed.)
First Revealed: Aug 01 2024 | 1:24 PM IST